

# Research and Reviews: Journal of Pharmacology and Toxicological Studies

## Overview on Alzheimer's and Parkinson's Disease

Sai Ram Seshu R\*

Department of Biotechnology, Andhra University, Visakhapatnam.

### Commentary Article

Received: 18/06/2015

Accepted: 26/07/2015

Published: 29/07/2015

#### \*For Correspondence

Department of Biotechnology,  
Andhra University,  
Visakhapatnam, Andhra Pradesh, India.

E-mail: [rramseshu@yahoo.co.in](mailto:rramseshu@yahoo.co.in)

The brain is vulnerable to a wide range of disorders that strike at each phase of life. Developmental disorder, for example, autism and dyslexia first show up in right on time adolescence. Psychiatric infections, for example, discouragement and schizophrenia are regularly analyzed in teenagers or early adulthood, in spite of the fact that their causes may lie much prior in life. What's more, as we age we turn out to be progressively defenseless to Alzheimer's disease, Parkinson's sickness, stroke, and different ailments <sup>[1]</sup>. Alzheimer's disease is a neurodegenerative disorder. From the genetic aspect of Alzheimer's disease which mainly caused due to mutation in one of the 3 genes namely amyloid precursor protein (app), presenilin 1 (ps-1), presenilin 2 (ps-2). In most of the cases the cause for the disease is unknown <sup>[2-4]</sup>. In USA approximately 5 million people are suffering with Alzheimer's disease. Among the affected people the disease symptoms are appearing before the age of 65. Some nerve cells deliver the synthetic dopamine, which transmits signals inside of the mind to create smooth development of muscles. In Parkinson's patients, 80 percent or a greater amount of these dopamine-delivering cells are harmed, dead, or deteriorated. In Parkinson's disease Psychiatric symptoms such as impulse control disorders and apathy, depression, anxiety and apathy. The vicinity of disregard has a critical negative effect on

personal satisfaction, incapacity and parental figure weight and may be an indicator of change to dementia in PD [4-7].

Clinically, AD is portrayed by loss of cortical, subcortical neurons and neural connections Parkinson's disease is portrayed by trouble in looking after parity, issues with ambulation, resting tremors, bradykinesia, and solidness of the appendages and trunk. Therapeutically, PD is characterized by the loss of dopaminergic neurons inside of the substantia nigra standards compacta with ensuing loss of striatal dopaminergic projections [8]. Amyotrophic horizontal sclerosis, otherwise called Lou Gehrig's infection, an issue of engine neurons depicted by muscle shortcoming, stumbling, dropping things, anomalous weakness of the arms and/or legs, slurred discourse, muscle spasms and jerks [9].

The diagnosis of Parkinson's disease can be done in different ways they are 1) Genetic testing, 2) neuroimaging, 3) Olfactory system testing and autonomic system testing.

In some cases disease may be inherited. 15 to 25 percent of people with PD have a known relative with the disease. Individuals with one or all the more close relatives who have Parkinson's are having high risk of getting this disease, however the risk of getting PD is still only 2 to 5 percent unless the family has a known genetic mutation for the disease [10].

There are a few qualities that are connected to Parkinson's disease. The main to be distinguished quality was alpha-synuclein or SNCA. Inherited cases of Parkinson's disease are created by changes in the LRRK2, PARK2 or parkin, PARK7 or DJ-1, PINK1, or SNCA qualities, or by transformations in qualities that have not yet been distinguished [11-13].

A survey was conducted in a hospital. Nearly 761 people who admitted with Parkinson's disease 15% are management PD and 39% were falls. The factors are orthostatic hypotension, e hips or knees, diuretics, anti-depressants or dehydration, imbalance resulting from tranquillizers, with this experiment .205 fallers, 51% fell, 78% fell once and 22% fell more than once [14-16]. Environmental contaminants also play a major role in spreading of the chronic diseases. Basic and helpful research in Alzheimer's ailment (AD) centered for quite a while only on psychological perspectives. Notwithstanding, AD additionally habitually includes complex disorders of influence and behaviour, which are at present gathered under the heading 'behavioral and mental signs and manifestations of dementia' (BPSSD). A few rating devices have been created throughout the years on the premise of a mixed bag of source information [17,18].

Pesticides poisonous quality has been unmistakably shown to change neurological capacities and various epidemiological studies have demonstrated a relationship between pesticides introduction and the etiology of Parkinson's malady. Pesticide poisonous quality relies on upon the dopamine transporters hereditary variability <sup>[19]</sup> or GST polymorphisms. In this way, a superior expectation of the hereditary inclination in the setting of ecological exposures will be vital for the counteractive action of incessant illnesses. At last, the checking of biomarkers connected with hereditary inclination on people presented to pesticides ought to move the field toward a superior general medical advantage <sup>[20]</sup>.

The vicinity of disregard has a critical negative effect on personal satisfaction, incapacity and parental figure weight and may be an indicator of change to dementia Alzheimer's disease (AD) and Parkinson's infection (PD) posture noteworthy difficulties for fruitful advancement of new treatments, with an extremely high medication trial disappointment rate but then no sanction infection adjusting medications accessible <sup>[21]</sup>. Given the size of the difficulties, it has turn out to be clear that bigger joint efforts and multi-accomplice joint endeavors, pooling assets and expertise, are needed for the headway of strategies and devices that are discriminatingly expected to bolster drug improvement studies. Discriminating Path Institute's Coalition against Major Diseases was shaped in 2008, at a time preceding the period of open private organizations, with the mission of streamlining and de-gambling medication improvement for Alzheimer's and Parkinson's disease. Since its inception, the consortium has accomplished a few turning points including improvement of accord information norms for AD and PD, a bound together clinical trial database embodied placebo information from AD remedial trials and administrative underwriting of medication improvement devices <sup>[22]</sup>.

There is request on group pathologists to perform post-mortems to affirm the clinical conclusion of Alzheimer's infection, the most widely recognized reason for dementia in our undeniably aging society <sup>[23]</sup>. Yet numerous pathologists are hesitant to inspect examination brains in light of the fact that they have little involvement with neuropathology and with the basic histopathologic staining strategies expected to assess dementia cases <sup>[24]</sup>.

Both Alzheimer's and Parkinson's infection have an onset that is late in life, for the most part after the age of 50. Both infections are neurodegenerative, implying that cerebrum cells (neurons) get to be damaged and die during the disease <sup>[25]</sup>. They are additionally both dynamic, so they deteriorate over the long haul. In the late phases of both diseases, the neurodegeneration can eventually prompt dementia

## References

1. Jana P, et al. Epidemiology and Genetics of Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2015; 5:172.
2. Avila J. A Possible Role for GSK3 in the Impaired Neurogenesis and Memory Loss Associated with Alzheimer's Disease and Aging. J Alzheimers Dis Res. 2011; 1:102e.
3. Ghribi O. Do Increased Levels of Oxysterols Underlie Alzheimer's Disease/Parkinson's Disease Overlap? J Alzheimers Dis. 2012; 2:e111.
4. Avila J. A Possible Role for GSK3 in the Impaired Neurogenesis and Memory Loss Associated with Alzheimer's Disease and Aging. J Alzheimers Dis Res. 2011; 1:102e.
5. Stephenson D, et al. Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases. J Alzheimers Dis Parkinsonism. 2015; 5: 183.
6. Krishnamurthi N, et al. Comparison of Parkinson Disease Patients Who Fell Once with Patients Who Fell More than Once (Recurrent Fallers). J Alzheimers Dis Parkinsonism. 2014; 4: 140.
7. Lieberman A, et al. Comparison of Parkinson Disease Patients Who Fell Once with Patients Who Fell More than Once (Recurrent Fallers). J Alzheimers Dis Parkinsonism. 2014; 4: 140.
8. Singh M and Ramassamy C. Environmental Exposure to Pesticides and Neurodegenerative Diseases. J Alzheimers Dis Parkinsonism .2012; 2:e116.
9. Jana P, et al. Epidemiology and Genetics of Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2015; 5: 172.
10. Lukiw WJ, et al. Microbial Sources of Amyloid and Relevance to Amyloidogenesis and Alzheimer's Disease (AD). J Alzheimers Dis Parkinsonism. 2015; 5:17.
11. Mushtaq G, et al. Impaired Glucose Metabolism in Alzheimer's disease and Diabetes. Enz Eng. 2014; 4:124.
12. Pallanti S and Marras A. Transcranial Magnetic Stimulation in Alzheimer's Disease: A Review of Investigational and Therapeutic Findings. J Alzheimers Dis Parkinsonism. 2015; 5:187.
13. D, Brumfield M, et al. Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition against Major Diseases. J Alzheimers Dis Parkinsonism. 2015; 5: 183.
14. Devasena T and Francis AP. Nanotoxicity-Induced Alzheimer Disease and Parkinsonism: Not Further than Diagnosis. J Alzheimers Dis Parkinsonism. 2015; 5:178.

15. Block A, et al. Abnormal Protein Profiles in Hippocampus of Mouse Models of Down Syndrome: Similarities with Alzheimer's Disease. *J Alzheimers Dis Parkinsonism*. 2014; 4:138.
16. Pompeu JE, et al. Safety, Feasibility and Effectiveness of Balance and Gait Training Using Nintendo Wii Fit Plus™ on Unstable Surface in Patients with Parkinson's Disease: A Pilot Study. *J Alzheimers Dis Parkinsonism*. 2014; 4:136.
17. Barz H, et al. Neuronal Impulse Theory and Alzheimer's Disease. *J Alzheimers Dis Parkinsonism*. 2014; 4:134.
18. Perea RD, et al. A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease. *J Alzheimers Dis Parkinsonism*. 2013; 3:123.
19. James LE and Asuni AA. Parkinson's Disease and the "Sunshine" Vitamin. *J Alzheimers Dis Parkinsonism*. 2013; 3:120.
20. Lu'o'ng Kvq, Nguyen LTH. Environmental Factors in Alzheimer's and Parkinson's Diseases. *J Alzheimers Dis Parkinsonism*. 2013; 3:119.
21. Ohyagi Y and Miyoshi K. Aluminum and Alzheimer's Disease: An Update. *J Alzheimers Dis Parkinsonism*. 2013; 3:118.
22. Madeo J and Elsayad C. The Role of Oxidative Stress in Alzheimer's Disease. *J Alzheimers Dis Parkinsonism*. 2013; 3:116.
23. Downer EJ. Toll-Like Receptor Signaling in Alzheimer's Disease Progression. *J Alzheimers Dis Parkinsonism*. 2013; S10:006.
24. Carman A, et al. Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. *J Alzheimers Dis Parkinsonism*. 2013; S10:007.
25. Vann A .Alzheimer's Behaviors or Coincidences? *J Alzheimers Dis Parkinsonism*. 2013; 3: 111.